Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML. 2019

S Haubner, and F Perna, and T Köhnke, and C Schmidt, and S Berman, and C Augsberger, and F M Schnorfeil, and C Krupka, and F S Lichtenegger, and X Liu, and P Kerbs, and S Schneider, and K H Metzeler, and K Spiekermann, and W Hiddemann, and P A Greif, and T Herold, and M Sadelain, and M Subklewe
Department of Medicine III, University Hospital, LMU Munich, Munich, Germany.

Targeted immunotherapy in acute myeloid leukemia (AML) is challenged by the lack of AML-specific target antigens and clonal heterogeneity, leading to unwanted on-target off-leukemia toxicity and risk of relapse from minor clones. We hypothesize that combinatorial targeting of AML cells can enhance therapeutic efficacy without increasing toxicity. To identify target antigen combinations specific for AML and leukemic stem cells, we generated a detailed protein expression profile based on flow cytometry of primary AML (n = 356) and normal bone marrow samples (n = 34), and a recently reported integrated normal tissue proteomic data set. We analyzed antigen expression levels of CD33, CD123, CLL1, TIM3, CD244 and CD7 on AML bulk and leukemic stem cells at initial diagnosis (n = 302) and relapse (n = 54). CD33, CD123, CLL1, TIM3 and CD244 were ubiquitously expressed on AML bulk cells at initial diagnosis and relapse, irrespective of genetic characteristics. For each analyzed target, we found additional expression in different populations of normal hematopoiesis. Analyzing the coexpression of our six targets in all dual combinations (n = 15), we found CD33/TIM3 and CLL1/TIM3 to be highly positive in AML compared with normal hematopoiesis and non-hematopoietic tissues. Our findings indicate that combinatorial targeting of CD33/TIM3 or CLL1/TIM3 may enhance therapeutic efficacy without aggravating toxicity in immunotherapy of AML.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009364 Neoplasm Recurrence, Local The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site. Local Neoplasm Recurrence,Local Neoplasm Recurrences,Locoregional Neoplasm Recurrence,Neoplasm Recurrence, Locoregional,Neoplasm Recurrences, Local,Recurrence, Local Neoplasm,Recurrence, Locoregional Neoplasm,Recurrences, Local Neoplasm,Locoregional Neoplasm Recurrences,Neoplasm Recurrences, Locoregional,Recurrences, Locoregional Neoplasm
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D001853 Bone Marrow The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells. Marrow,Red Marrow,Yellow Marrow,Marrow, Bone,Marrow, Red,Marrow, Yellow
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths

Related Publications

S Haubner, and F Perna, and T Köhnke, and C Schmidt, and S Berman, and C Augsberger, and F M Schnorfeil, and C Krupka, and F S Lichtenegger, and X Liu, and P Kerbs, and S Schneider, and K H Metzeler, and K Spiekermann, and W Hiddemann, and P A Greif, and T Herold, and M Sadelain, and M Subklewe
July 2011, [Rinsho ketsueki] The Japanese journal of clinical hematology,
S Haubner, and F Perna, and T Köhnke, and C Schmidt, and S Berman, and C Augsberger, and F M Schnorfeil, and C Krupka, and F S Lichtenegger, and X Liu, and P Kerbs, and S Schneider, and K H Metzeler, and K Spiekermann, and W Hiddemann, and P A Greif, and T Herold, and M Sadelain, and M Subklewe
May 2015, Nihon rinsho. Japanese journal of clinical medicine,
S Haubner, and F Perna, and T Köhnke, and C Schmidt, and S Berman, and C Augsberger, and F M Schnorfeil, and C Krupka, and F S Lichtenegger, and X Liu, and P Kerbs, and S Schneider, and K H Metzeler, and K Spiekermann, and W Hiddemann, and P A Greif, and T Herold, and M Sadelain, and M Subklewe
February 2021, Blood,
S Haubner, and F Perna, and T Köhnke, and C Schmidt, and S Berman, and C Augsberger, and F M Schnorfeil, and C Krupka, and F S Lichtenegger, and X Liu, and P Kerbs, and S Schneider, and K H Metzeler, and K Spiekermann, and W Hiddemann, and P A Greif, and T Herold, and M Sadelain, and M Subklewe
June 2006, Zhonghua zhong liu za zhi [Chinese journal of oncology],
S Haubner, and F Perna, and T Köhnke, and C Schmidt, and S Berman, and C Augsberger, and F M Schnorfeil, and C Krupka, and F S Lichtenegger, and X Liu, and P Kerbs, and S Schneider, and K H Metzeler, and K Spiekermann, and W Hiddemann, and P A Greif, and T Herold, and M Sadelain, and M Subklewe
August 1995, Leukemia,
S Haubner, and F Perna, and T Köhnke, and C Schmidt, and S Berman, and C Augsberger, and F M Schnorfeil, and C Krupka, and F S Lichtenegger, and X Liu, and P Kerbs, and S Schneider, and K H Metzeler, and K Spiekermann, and W Hiddemann, and P A Greif, and T Herold, and M Sadelain, and M Subklewe
May 2019, Aging,
S Haubner, and F Perna, and T Köhnke, and C Schmidt, and S Berman, and C Augsberger, and F M Schnorfeil, and C Krupka, and F S Lichtenegger, and X Liu, and P Kerbs, and S Schneider, and K H Metzeler, and K Spiekermann, and W Hiddemann, and P A Greif, and T Herold, and M Sadelain, and M Subklewe
May 2016, International journal of hematology,
S Haubner, and F Perna, and T Köhnke, and C Schmidt, and S Berman, and C Augsberger, and F M Schnorfeil, and C Krupka, and F S Lichtenegger, and X Liu, and P Kerbs, and S Schneider, and K H Metzeler, and K Spiekermann, and W Hiddemann, and P A Greif, and T Herold, and M Sadelain, and M Subklewe
September 2012, Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences,
S Haubner, and F Perna, and T Köhnke, and C Schmidt, and S Berman, and C Augsberger, and F M Schnorfeil, and C Krupka, and F S Lichtenegger, and X Liu, and P Kerbs, and S Schneider, and K H Metzeler, and K Spiekermann, and W Hiddemann, and P A Greif, and T Herold, and M Sadelain, and M Subklewe
November 2009, Future oncology (London, England),
S Haubner, and F Perna, and T Köhnke, and C Schmidt, and S Berman, and C Augsberger, and F M Schnorfeil, and C Krupka, and F S Lichtenegger, and X Liu, and P Kerbs, and S Schneider, and K H Metzeler, and K Spiekermann, and W Hiddemann, and P A Greif, and T Herold, and M Sadelain, and M Subklewe
January 2024, bioRxiv : the preprint server for biology,
Copied contents to your clipboard!